Why the study?
The comparative efficacy and safety of pharmacological strategies for Lp(a) lowering, including PCSK9 inhibitors, siRNA therapies, ASOs, and muvalaplin, needed systematic evaluation.
Population
83 RCTs with 71 datasets involving 46,984 participants
Comparison
PCSK9 inhibitors, siRNA therapies, ASOs, and muvalaplin vs placebo
Design
Systematic review and network meta-analysis of randomized controlled trials
Answers are grounded in this paper and cite their sources.
Olpasiran yields the largest Lp(a) reduction among targeted therapies; extends meta-analytic support for Lp(a) lowering in cardiovascular risk management.
Aim To compare the efficacy and safety of pharmacological strategies for lipoprotein(a) [Lp(a)] lowering, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, small interfering RNA (siRNA) therapies, antisense oligonucleotides (ASOs), and muvalaplin. Methods PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through April 23, 2026, for randomized controlled trials (RCTs) evaluating these therapies for Lp(a) lowering. Primary outcomes were percentage and absolute changes in Lp(a). Safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) were assessed as exploratory outcomes. Subgroup, sensitivity, and meta-regression analyses were performed, and risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Results A total of 83 RCTs were included, with 71 datasets involving 46,984 participants contributing to the Lp(a) percentage-change network. Lp(a)-targeted therapies produced substantially greater reductions in Lp(a) than non-Lp(a)-targeted therapies. Among Lp(a)-targeted therapies, substantial percentage-point differences were observed with olpasiran (MD -92.06, 95% CI -107.91 to -76.21), muvalaplin (MD -61.49, 95% CI -80.26 to -42.72), and pelacarsen (MD -54.15, 95% CI -76.75 to -31.55). However, overlapping confidence intervals precluded establishing a definitive treatment hierarchy. PCSK9 inhibitors produced more modest reductions. No statistically detectable increase in SAEs was observed versus placebo. Several agents had increased odds of AEs or injection-site reactions, whereas no increased odds of headache were detected. Exploratory meta-regression associated higher study-level baseline Lp(a) with greater reductions across all therapies and among RNA-based therapies and muvalaplin. Subgroup and sensitivity analyses yielded findings generally consistent with the primary analysis. The certainty of evidence was predominantly low or very low, warranting cautious interpretation of the comparative estimates. Conclusion Lp(a)-targeted therapies, particularly siRNA-based agents, achieved substantially greater reductions in circulating Lp(a) than non-Lp(a)-targeted therapies. These findings provide estimates of comparative biochemical efficacy for Lp(a) lowering, but not comparative effectiveness for preventing cardiovascular events. Although no statistically detectable increase in SAEs was observed over the available follow-up, adequately powered cardiovascular outcome trials with longer follow-up are required to establish long-term safety and determine whether these biochemical effects translate into cardiovascular benefit. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251207571 , identifier CRD420251207571.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: